U.S. Interventional Cardiology Market Revenue & Forecast Analysis, 2026-2035

The U.S. interventional cardiology market size was estimated at USD 4.45 billion in 2025. The market is expected to grow at a CAGR of 5.9% from USD 4.69 billion in 2026 to USD 7.83 billion in 2035. The market expansion is supported by the wider deployment of catheterisation laboratories, growing utilisation of drug-eluting balloons, increasing use of intracoronary imaging and physiological assessment, advances in lesion-preparation technologies, and the expanding availability of same-day interventional care pathways.

Published: August 25, 2026
100 Pages

Market Overview

A 2024 U.S. study published in the Journal of the Society for Cardiovascular Angiography & Interventions analysed more than 2.2 million PCI hospitalisations and found that intracoronary imaging was used in 9.2% of procedures, highlighting the growing adoption of advanced imaging techniques in interventional cardiology practice.

The U.S. interventional cardiology market has shown steady historical growth, driven by the increasing prevalence of coronary artery disease, rising adoption of percutaneous coronary interventions, and continued advances in catheter-based treatment technologies. Increasing need for less invasive cardiovascular procedures in hospitals and specialised cardiac centers has prompted broader use of coronary stents, angioplasty balloons, catheters, guidewires, and related interventional devices. For instance, in 2024, Boston Scientific received FDA approval for its AGENT Drug-Coated Balloon to treat coronary in-stent restenosis, supporting the wider adoption of advanced technologies for complex coronary interventions.

The U.S. interventional cardiology market is projected to sustain favourable growth throughout the forecast period due to the growing demand for minimally invasive cardiovascular procedures and healthcare providers' heightened focus on procedural precision, treatment effectiveness, recovery time, and patient outcomes. The growing use of drug-coated balloons, intravascular imaging, advanced stent technologies, and other catheter-based solutions is anticipated to create more opportunities for producers. For instance, in 2024, Boston Scientific completed its acquisition of Silk Road Medical, expanding its minimally invasive vascular intervention portfolio and supporting the continued development of catheter-based treatment technologies in the U.S.

U.S. Interventional Cardiology Market Overview

Base Year Market Size (2025): USD 4.45 Billion

CAGR: 5.9%

Forecast Year Market Size (2035): USD 7.83 Billion

Major Players:

  • Boston Scientific Corporation

  • Medtronic plc

  • Abbott Laboratories

  • Edwards Lifesciences Corporation

  • Terumo Corporation

U.S. Interventional Cardiology Market Trend

The U.S. interventional cardiology market is experiencing significant progress, fueled by increasing use of complex coronary interventions, expansion of structural heart procedures, adoption of advanced lesion-modification technologies, and growing integration of artificial intelligence and robotics.

· A significant trend is the increasing use of advanced lesion-modification techniques, including intravascular lithotripsy and atherectomy, particularly for treating heavily calcified coronary lesions.

· The market is witnessing expanding adoption of structural heart interventions, including transcatheter valve therapies and left atrial appendage closure, broadening the scope of catheter-based cardiovascular treatment.

· A growing trend is emerging toward coronary CT angiography for PCI planning, as clinicians increasingly use anatomical information to improve procedural preparation and treatment strategies.

· Artificial intelligence is also gaining importance, with emerging applications in image processing, procedural planning, risk assessment, and decision support for interventional cardiology.

· Additionally, robotic and technology-assisted interventions are attracting greater attention, supporting procedural consistency while potentially reducing radiation exposure and improving catheter manipulation.

Collectively, the growing use of lesion-modification technologies, structural heart interventions, CT-guided planning, artificial intelligence, and robotic assistance are significant trends influencing the U.S. interventional cardiology market.

U.S. Interventional Cardiology Market Analysis

By Product Type

Coronary stents dominate the U.S. interventional cardiology market due to their established role in maintaining vessel patency and their widespread use during coronary interventions

Based on product type, the U.S. interventional cardiology market is categorised into coronary stents, PTCA balloon catheters, intravascular imaging catheters and pressure guidewires, and accessory devices. The coronary stents segment holds the largest market share in 2025.

By Application

Coronary artery disease dominates the U.S. interventional cardiology market due to its high treatment volume and widespread use of PCI-based interventions

Based on application, the U.S. interventional cardiology market is categorised into coronary artery disease (CAD), acute myocardial infarction (AMI), and chronic total occlusion (CTO). The coronary artery disease (CAD) segment holds the largest market share in 2025.

By End-use

Hospitals dominate the U.S. interventional cardiology market due to their advanced cardiac infrastructure and capacity to perform complex cardiovascular interventions.

Based on end-use, the U.S. interventional cardiology market is categorised into hospitals, cath labs, ambulatory surgical centers (ASCs), and specialty cardiac centers. The hospitals segment holds the largest market share in 2025.

Key Companies Profiled

The U.S. interventional cardiology market is moderately consolidated, with established cardiovascular device companies competing across coronary stents, balloon catheters, intravascular imaging, guidewires, and structural heart technologies. Competition is mainly determined by device performance, clinical evidence, procedural versatility, physician adoption, regulatory approvals, and distribution reach. Boston Scientific, Medtronic, Abbott, Edwards Lifesciences, and Terumo are key players with strong footholds across important interventional cardiology product categories.

The competitive environment is increasingly influenced by advanced stent technologies, intravascular imaging, lesion-modification devices, structural heart interventions, and next-generation catheter systems. Companies are concentrating on improving deliverability, procedural efficiency, device safety, and treatment outcomes while expanding their cardiovascular technology portfolios. Product launches, clinical evidence, strategic acquisitions, physician partnerships, and healthcare-provider contracts are forecasted to remain vital strategies for strengthening market presence in the U.S.

U.S. Interventional Cardiology Market Companies:

  • Abbott Laboratories

  • B. Braun SE

  • Biosensors International Group, Ltd.

  • BIOTRONIK SE & Co. KG

  • Boston Scientific Corporation

  • Cook Medical LLC

  • Cordis

  • Edwards Lifesciences Corporation

  • Integer Holdings Corporation

  • Medtronic plc

  • Merit Medical Systems, Inc.

  • Penumbra, Inc.

  • Teleflex Incorporated

  • Terumo Corporation

  • W. L. Gore & Associates, Inc.

Market Segmentation

This study provides revenue growth and emerging trends across global, regional, and country levels from 2021 to 2035, segmenting the U.S. Interventional Cardiology market by-

Product Type (Revenue in USD Million, 2021 - 2035)

  • Coronary Stents

    • Drug-Eluting Stents (DES)

    • Bare Metal Stents (BMS)

    • Bioresorbable Scaffolds (BRS)

  • PTCA Balloon Catheters

    • Normal

    • Specialty

    • Drug-Coated

  • Intravascular Imaging Catheters and Pressure Guidewires

  • Accessory Devices

    • PTCA Guidewires

    • PTCA Guiding

    • Catheters

    • Introducer Sheaths

Application (Revenue in USD Million, 2021 - 2035)

  • Coronary Artery Disease (CAD)

  • Acute Myocardial Infarction (AMI)

  • Chronic Total Occlusion (CTO)

End-use (Revenue in USD Million, 2021 – 2035)

  • Hospitals

  • Cath Labs

  • Ambulatory Surgical Centers (ASCs)

  • Specialty Cardiac Centers

Table of Content

1. Methodology and Scope

1.1. Scope of the Study

1.1.1. Market Segmentation

1.1.2. Market Definition

1.1.3. Inclusions and Exclusions of the Study

1.2. Research Design

1.2.1. Base Year, Historical Data, and Forecast Period

1.2.2. Data Collection Methods

1.2.2.1. Secondary Sources

1.2.2.2. Primary Sources

1.2.3. Research Methodology

1.2.3.1. Base Year Calculation/ Parent Market Analysis, Company/ Brand Share Analysis, 2025 (Top-down Approach)

1.2.3.2. Volume-Price Approach (Bottom-up Approach)

1.2.3.3. Data Triangulation

1.2.4. Forecasting Model

1.3. Research Assumptions

1.4. Validation and Data Quality Control

1.5. List of Primary Sources

1.6. List of Secondary Sources

2. Executive Summary

2.1. Market Overview

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

3. Industry Outlook

3.1. Industry Ecosystem Analysis

3.2. Parent/ Ancillary Market Analysis

3.3. Market Dynamics

3.3.1. Drivers

3.3.2. Restraints/ Challenges

3.3.3. Opportunities

3.4. Value Chain Analysis

3.5. Technology Roadmap

3.6. Porters Analysis

3.7. PESTLE Analysis

4. Market Estimates and Forecasts, By Product Type, 2021 - 2035 (Market Size in USD Mn)

4.1. Coronary Stents

4.1.1. Drug-Eluting Stents (DES)

4.1.2. Bare Metal Stents (BMS)

4.1.3. Bioresorbable Scaffolds (BRS)

4.2. PTCA Balloon Catheters

4.2.1. Normal

4.2.2. Specialty

4.2.3. Drug-Coated

4.3. Intravascular Imaging Catheters and Pressure Guidewires

4.4. Accessory Devices

4.4.1. PTCA Guidewires

4.4.2. PTCA Guiding

4.4.3. Catheters

4.4.4. Introducer Sheaths

5. Market Estimates and Forecasts, By Application, 2021 – 2035 (USD Mn)

5.1. Coronary Artery Disease (CAD)

5.2. Acute Myocardial Infarction (AMI)

5.3. Chronic Total Occlusion (CTO)

6. Market Estimates and Forecasts, By End-use, 2021 – 2035 (USD Mn)

6.1. Hospitals

6.2. Cath Labs

6.3. Ambulatory Surgical Centers (ASCs)

6.4. Specialty Cardiac Centers

7. Market Estimates and Forecasts, By U.S., 2021 - 2035 (USD Mn)

7.1.1. U.S.

7.1.1.1. U.S. Interventional Cardiology Market Estimates and Forecasts to 2035 (USD Mn)

7.1.1.2. Market Dynamics

7.1.1.3. Competitive Landscape

7.1.1.4. Regulatory Framework

7.1.1.5. Reimbursement Scenario

8. Competitive Landscape

8.1. Company Market Share Analysis, 2025

8.2. Company Tier Structure

8.3. List of Major Suppliers, By Key Countries

8.4. Key Company Positioning Analysis

8.5. Company Profile

8.5.1. Abbott Laboratories

8.5.2. B. Braun SE

8.5.3. Biosensors International Group, Ltd.

8.5.4. BIOTRONIK SE & Co. KG

8.5.5. Boston Scientific Corporation

8.5.6. Cook Medical LLC

8.5.7. Cordis

8.5.8. Edwards Lifesciences Corporation

8.5.9. Integer Holdings Corporation

8.5.10. Medtronic plc

8.5.11. Merit Medical Systems, Inc.

8.5.12. Penumbra, Inc.

8.5.13. Teleflex Incorporated

8.5.14. Terumo Corporation

8.5.15. W. L. Gore & Associates, Inc.

9. Analyst Perspective

10. Related Reports

Revolution Insights Briefs

Stay informed with updates on related market reports and key industry topics.